Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes

Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription. Novo Nordisk's Wegovy pill also rec...

Reuters
Britain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the UK. Foundayo will launch privately later this month via prescription.
Britain's ​medicines regulator on Monday authorised Eli Lilly's pill, Foundayo, ​for weight management and type 2 diabetes, making it the first country in Europe to green light the treatment for both conditions.

"Whilst this tablet is approved for use ‌in the ⁠UK, it ⁠is not available currently via the NHS," the Medicines and Healthcare products Regulatory Agency, or ​MHRA, said.

Also Read: Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity


The approval marks the second GLP-1 oral pill cleared in the UK after Novo secured its nod for the Wegovy pill in June, intensifying competition between the two pharma majors.

A Lilly spokesperson told Reuters Foundayo will ​launch in the UK later this month via ⁠private prescription. ‌He added the pill would carry a lower UK ​list price ​privately than Mounjaro, which is listed at £330 for a ⁠month's supply, but did not provide further details on pricing.

Foundayo ​is under review in the European Union. Meanwhile, Novo ​Nordisk's Wegovy pill has won a positive recommendation from the European Medicines Agency, with a final approval decision pending from the European Commission.
ADVERTISEMENT

The weight-loss drug market, long dominated by injectable therapies from Eli Lilly and Novo Nordisk, is increasingly expanding into oral treatments. But while pills are ‌gaining traction rapidly, injectables remain the market leaders, aided by their established efficacy and once-weekly dosing schedules.

Also Read: Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriers

Lilly's GLP-1 tablet, a ​once-daily drug ​that targets the GLP-1 ⁠hormone, has been gaining momentum in the U.S. since its approval and launch in April, but still lags rival Novo Nordisk's Wegovy pill.

Foundayo's chief advantage ​is convenience as it can be taken once daily without food or water restrictions, while the Wegovy pill requires patients to take it on an empty stomach with a small amount of water and wait 30 minutes before consuming food, beverages or other medications.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › Business › Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetes
Text Size:AAA
Success
This article has been saved

*

+